NCT02174432View on ClinicalTrials.gov

Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo Nodularis

PHASE2/PHASE3CompletedINTERVENTIONAL

Enrollment

36

Participants

Timeline

Start Date

August 15, 2015

Primary Completion Date

September 3, 2017

Study Completion Date

September 3, 2017

Conditions

Prurigo NodularisNodularis PrurigoPrurigo

Interventions

DRUG

nalbuphine HCl ER

nalbuphine HCl ER BID for up to 50 weeks

Trial Locations (1)

Unknown

University of Münster, Münster

Sponsors

Lead Sponsor

Trevi Therapeutics

All Listed Sponsors

lead

Trevi Therapeutics

INDUSTRY

NCT02174432 - Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo Nodularis | Biotech Hunter | Biotech Hunter